Zolbetuximab plus mFOLFOX6 for Claudin-18.2-Positive Advanced Gastric Cancer with Multiple Bone Metastases and Disseminated Intravascular Coagulation: A Case Report
Case Reports in Oncology · 2026-08-22 · 19 (1) · 1459-1467
DOI: 10.1159/cro/abzag021 ↗Abstract
Introduction: Advanced gastric cancer (AGC) complicated by bone marrow carcinomatosis (BMC) and disseminated intravascular coagulation (DIC), for which there is currently no standard treatment, has a poor prognosis. Case Presentation: We report herein a 75-year-old male patient with claudin-18.2 (CLDN18.2)-positive, HER2-negative AGC who presented with multiple bone metastases and overt DIC, which raised the index of suspicion for BMC. Although his poor performance status (PS) was attributed primarily to cancer-related pain and coagulopathy, systemic chemotherapy was started with mFOLFOX6. Early in the treatment course, acute-on-chronic subdural hematoma developed in the presence of severe thrombocytopenia, and the patient underwent burr-hole drainage after receiving intensive transfusion support. Once CLDN18.2 positivity was confirmed, zolbetuximab was added from cycle 2. The DIC parameters improved and stabilized. Hematological recovery followed, the primary lesion showed regression on imaging, and his PS improved modestly. He received seven cycles of zolbetuximab plus mFOLFOX6. However, his PS did not recover sufficiently to permit the continuation of outpatient infusional chemotherapy, prompting a treatment transition to S-1 monotherapy followed by best supportive care. The patient survived 233 days after the initial diagnosis. Conclusion: The present case demonstrated that zolbetuximab-containing therapy combined with multidisciplinary management can be a feasible option for selected patients with CLDN18.2-positive AGC complicated by DIC and clinically suspected BMC.
EUVIMED